We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MorphoSys and the University of Melbourne File new Patent Applications in MOR103 Program
News

MorphoSys and the University of Melbourne File new Patent Applications in MOR103 Program

MorphoSys and the University of Melbourne File new Patent Applications in MOR103 Program
News

MorphoSys and the University of Melbourne File new Patent Applications in MOR103 Program

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MorphoSys and the University of Melbourne File new Patent Applications in MOR103 Program"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MorphoSys AG and the University of Melbourne announced an agreement to cooperate on investigating new therapeutic applications for MorphoSys's MOR103 program. MOR103, a HuCAL antibody against human GM-CSF, is currently in development for the treatment of rheumatoid arthritis (RA).

The collaboration will focus on new therapeutic areas in which GM-CSF has recently been implicated in as-yet unpublished work of researchers at the University of Melbourne. As part of the expanded relationship, new patent applications have been filed, which are intended to broaden the patent position of the anti-GM-CSF approach.

Under the terms of the agreement, MorphoSys will fund research activities at the University of Melbourne in multiple new indications. The University of Melbourne will receive an upfront payment and will be entitled to research funding, clinical milestone and royalty payments. Further financial details were not disclosed.

"The University of Melbourne, and in particular the research group of Professor John Hamilton, has long been at the cutting edge of research on GM-CSF. We are excited to be able to deepen our relationship with MorphoSys and help speed the transition of these laboratory insights into clinical applications for the benefit of patients", said Dr Charlie Day, CEO of Melbourne Ventures, the technology commercialization company for the University of Melbourne.

"Researchers at the University of Melbourne have now generated evidence for the involvement of GM-CSF in indications beyond those that were already known", commented Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG. "We look forward to working closely with them to explore the potential of targeting GM-CSF in these additional indications, and expand still further the patent position around inhibitors of GM-CSF. Meanwhile, development of our anti-GM-CSF antibody MOR103 in RA continues according to plan."

In 2007, MorphoSys signed an agreement with the University of Melbourne, providing the company with an exclusive license to a patent family covering therapeutic uses of inhibitors of GM-CSF. The claims of the patent are directed to methods of ameliorating the effects of inflammation by administering to a patient an antibody directed against GM-CSF.

In November 2008, the U.S. Patent & Trademark Office (USPTO) issued the patent U.S. Patent No. 7,455,836, covering key uses of antibodies against GM-CSF. Human GM-CSF is already implicated in a number of medical conditions.
Advertisement